Treating socket discharge and discomfort: a crossover randomised trial of vitamin A ointment, low-dose steroid eyedrops and artificial tears.

Br J OphthalmolSep 22, 2026 (epub)
Clinical ResearchOphthalmology

Arthur Yu Xiang Liu, Stijn W Van Der Meeren, Adriaan D Coumou et al.

✦ AI-curated · Sources linked

In 30 seconds

This crossover randomized trial evaluated the effects of vitamin A ointment, artificial tears, and low-dose steroid drops on chronic irritation and discharge in 40 anophthalmic patients using ocular prostheses. Vitamin A ointment significantly improved irritation frequency and severity, as well as discharge frequency and severity, with p-values less than 0.05 for all outcomes. Fluorometholone did not show significant benefits.

Key findings

  • Vitamin A ointment reduced irritation frequency by -1.766 (95% CI -2.857 to -0.675, p<0.001).
  • Irritation severity decreased by -1.448 with vitamin A ointment (95% CI -2.564 to -0.332, p=0.004).
  • Artificial tears significantly reduced irritation frequency by -1.279 (95% CI -2.370 to -0.188, p=0.013).
  • Fluorometholone showed no significant reduction in irritation or discharge.

Why it matters

Understanding the effectiveness of different treatments for chronic irritation and discharge in anophthalmic patients can guide clinicians in personalizing care, potentially improving patient comfort and quality of life.

Source

PubMed · PMID 41781183

Published in Br J Ophthalmol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.